Last reviewed · How we verify
Fluticasone propionate-azelastine nasal spray
At a glance
| Generic name | Fluticasone propionate-azelastine nasal spray |
|---|---|
| Sponsor | Pamukkale University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- INTRANASAL FLUTICASONE VERSUS FLUTICASONE-AZELASTINE COMBINATION (PHASE4)
- Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis (PHASE4)
- Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Allergic Rhinitis (PHASE4)
- Bioequivalence Study of Azelastine Hydrochloride/ Fluticasone Propionate 137 Microgram/50 Microgram Nasal Spray and Dymista Nasal Spray (PHASE1)
- Observational Study to Evaluate the Actual Use and Effectiveness of Dymista® Nasal Spray in Asian Patients
- Allergic Rhinitis Combination Pharmacotherapy Efficacy Study (PHASE4)
- A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergic Rhinitis (PHASE2)
- Dymista Allergen Chamber - Onset of Action Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: